Dr. Vishal Gupta's ADVANTAGE — Diabetes, Thyroid & Endocrine Centre
Book a consult
Research & publications

Research only matters when patients benefit.

56 publications and presentations across ADA, EASD, ESE, ENDO and Indian journals — organised by the conditions they help treat.

Beyond Type 2 Diabetes Mellitus — Editor: Vishal Gupta (Jaypee)
Editor-in-Chief

Beyond Type 2 Diabetes Mellitus

First edition · Jaypee Brothers Medical Publishers. Edited by Dr Vishal Gupta, who also authored several of its chapters.

Forewords by Ashley Grossman, Altaf Patel, Harvy Chahal, Shanti Vijayaraghavan and Manoj Chaddha.

Obesity Research

  1. Gupta V, et al. Effect of oral semaglutide on weight & cardiac biomarkers in patients with hypothyroidism treated using liothyronine + levothyroxine combination therapy. Metabolism, Obesity and Diabetes. Endocrine Abstracts 2023;94:P349. doi:10.1530/endoabs.94.P349
  2. Gupta V. Comparison of Effectiveness of Canagliflozin 300 mg plus Gliptin vs. Oral Semaglutide plus SGLT2i on Cardiorenal Markers in T2DM Patients. Diabetes 2025;74(Suppl_1):30–PUB. doi:10.2337/db25-30-PUB

Diabetic Cardio-Renal Research

  1. Vishal Gupta. Comparison of the effect of up-titration of angiotensin receptor blocker (ARB) alone vs ARB plus finerenone on renal markers in type 2 diabetes with stage 1-3 nephropathy receiving SGLT2i therapy. Short Oral Station 20, SODA Area on Level 2 1150, 62nd EASD Annual Meeting, Milan, 29 September 2026.
  2. Vishal Gupta. 1393-P: Comparative Efficacy of Use of Combined Finerenone and Conventional Dose Angiotensin II Receptor Blockers vs. High-Dose ARB on Renal Markers in T2DM Patients with Stage 1–3 Diabetic Nephropathy Receiving SGLT2i. Diabetes 1 June 2026;75(Supplement_1):1393–P. doi:10.2337/db26-1393-P
  3. Gupta V. Comparison of effects of canagliflozin, dapagliflozin and empagliflozin on cardio-renal biomarkers in 150 patients with type 2 diabetes. 58th EASD Annual Meeting, short oral presentation 866; Sept 2022. (Conference resource: EASD media centre).
  4. Gupta V, et al. Canagliflozin may offer vascular and renal protection in patients with type 2 diabetes mellitus — an Indian perspective. Indian J Cardiol (Photon) 2019;112:145–165.
  5. Gupta V, et al. Comparison of cardiovascular (NT-proBNP) and renal biomarkers in 280 T2DM patients with microalbuminuria vs. normoalbuminuria. Diabetes 2019;68:2229-PUB. doi:10.2337/db19-2229-PUB
  6. Gupta V, Teli V. Subgroup analysis to evaluate effects of baseline characteristics on markers of renal and cardiovascular risk in type 2 diabetes patients treated with SGLT2 inhibitor (canagliflozin). Abstract P2418-PUB. American Diabetes Association 2017, San Diego, USA.
  7. Teli V, Gupta V. A real-life prospective study to evaluate effect of sodium-glucose co-transporter-2 inhibitor (canagliflozin) therapy on cardiovascular and renal markers in patients with type 2 diabetes mellitus. Poster P1204. American Diabetes Association 2017, San Diego, USA.

Diabetic Cardiac Research

  1. Gupta V, et al. Elevated NT-proBNP is associated with significant CT-left anterior descending coronary artery calcification score in T2DM. Diabetes 2023;72(Suppl_1):470-P. doi:10.2337/db23-470-P
  2. Gupta V, et al. Comparison of efficacy of canagliflozin 100 mg vs. canagliflozin 300 mg on hs-CRP in patients with type 2 diabetes mellitus. Diabetes 2020;69(Suppl_1):2219–PUB. doi:10.2337/db20-2219-PUB
  3. Gupta V, et al. Effect of sacubitril/valsartan combination therapy in type 2 diabetes mellitus patients with elevated NT-proBNP and preserved ejection fraction. Diabetes 2020;69(Suppl_1):1069–P. doi:10.2337/db20-1069-P
  4. Gupta V, et al. To evaluate the relationship between hs-CRP and NT-proBNP in 200 type 2 diabetes patients optimised for conventional cardiovascular and renal risk factors at the end of 2 years. Submission number A-19-346-EASD; Barcelona Sept 2019. (EASD resource).
  5. Gupta V, et al. Despite optimal use of angiotensin receptor blockers there exists substantial cardiovascular risk as suggested by elevated NT-proBNP in 259 T2DM patients. Diabetes 2019;68(Suppl_1):2210–PUB.
  6. Gupta V, et al. N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a strong predictor of cardiovascular risk in patients with type 2 diabetes optimised for conventional cardiovascular and renal risk factors, and its relationship with highly sensitive C-reactive protein (hs-CRP) at the end of 2 years. Indian J Cardiol (Photon) 2019;112:130–144.
  7. Gupta V, et al. To evaluate patient characteristics in those with elevated NT-proBNP in type 2 DM patients optimized for conventional CV risk factors on standard care for two years. Diabetes 2018;67(Suppl_1):1516–P. doi:10.2337/db18-1516-P
  8. Gupta V, et al. The role of NT-proBNP as a biomarker in evaluating residual cardiovascular risk in 200 type 2 DM patients optimized for conventional CV risk markers over two years. Diabetes 2018;67(Suppl_1):1513–P. doi:10.2337/db18-1513-P

Diabetic Hypertension Research

  1. Gupta V. Evaluating the Effect of Finerenone on Renal Markers in Patients with Diabetic Nephropathy (Stage 1–3) Receiving Angiotensin Receptor Blockers and SGLT2i Therapy. Diabetes 2025;74(Suppl_1):403–P. doi:10.2337/db25-403-P
  2. Gupta V, et al. Does sacubitril/valsartan combination therapy provide additional renal benefits in type 2 diabetes mellitus receiving canagliflozin? Diabetes 2021;70(Suppl_1):784–P. doi:10.2337/db21-784-P
  3. Gupta V, et al. Comparison of telmisartan vs. valsartan on cardiovascular and renal biomarkers in 84 patients with T2DM with microalbuminuria. Diabetes 2019;68(Suppl_1):1126–P. doi:10.2337/db19-1126-P
  4. Gupta V, et al. Effect of high dose vs. conventional dose angiotensin receptor blockers in 175 T2DM with microalbuminuria on CV (NT-proBNP) and renal biomarkers. Diabetes 2019;68(Suppl_1):1125–P. doi:10.2337/db19-1125-P
  5. Gupta V. Mineralocorticoid hypertension. Indian J Endocrinol Metab 2011;15(Suppl 4):S298–S312. PMID:22145132. PMCID:PMC3230101. doi:10.4103/2230-8210.86972

Pituitary Research

  1. Gupta V, et al. A case series of hypopituitarism presenting as nocturnal hypoglycaemia in patients with type 2 diabetes mellitus. Poster, ECE 2020 Sept. Endocrine Abstracts 2020;70:EP305. doi:10.1530/endoabs.70.EP305
  2. Gupta V, Patil S, Raval D, Gopani P. Pituitary apoplexy presenting as myocardial infarction. Indian J Endocrinol Metab 2014;18(2):232–233. PMID:24741524. PMCID:PMC3987278. doi:10.4103/2230-8210.129119
  3. Gupta V, Lee M. Growth hormone in chronic renal disease. Indian J Endocrinol Metab 2012;16(2):195–203. PMID:22470855. PMCID:PMC3313736. doi:10.4103/2230-8210.93736
  4. Gupta V, Nagpal RD, Venkatraman S, Patel A. Idiopathic granulomatous hypophysitis presenting as panhypopituitarism. The Endocrinologist 2010;20(3):102–104. doi:10.1097/TEN.0b013e3181dfd199
  5. Gupta V, Grossman A, Kapadia A, Thorat K. Acromegaly associated with a symptomatic Rathke’s cyst. Indian J Endocrinol Metab 2011;15(2):140–142. PMID:21731878. PMCID:PMC3125006. doi:10.4103/2230-8210.81950
  6. Gupta V. Adult growth hormone deficiency. Indian J Endocrinol Metab 2011;15(Suppl 3):S197–S202. PMID:22029024. PMCID:PMC3183535. doi:10.4103/2230-8210.84865

Diabetes

  1. Gupta V, et al. An observational study to evaluate change in dose requirement of standard glucose-lowering, lipid-lowering, and antihypertensive therapy treated with SGLT2 inhibitor (canagliflozin) over one year, in fifty T2DM patients. Diabetes 2018;67(Suppl_1):1165–P. doi:10.2337/db18-1165-P
  2. Gupta V, Willis M, Johansen P, Nilsson A, Shah M, Mane A, Neslusan C. Long-term clinical benefits of canagliflozin 100 mg versus sulfonylurea in patients with type 2 diabetes mellitus inadequately controlled with metformin in India. Value Health Reg Issues 2019 May;18:65–73. PMID:30502662. doi:10.1016/j.vhri.2018.06.002
  3. Gupta V, Canovatchel W, Lokesh BN, Santani R, Garodia N. Sodium-glucose cotransporter-2 inhibitors: moving beyond the glycemic treatment goal. Indian J Endocrinol Metab 2017;21(6):909–918. PMID:29285458. doi:10.4103/ijem.IJEM_85_17
  4. Gupta V, Baabbad R, Hammerby E, Nikolajsen A, Shafie AA. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or NPH to biphasic insulin aspart 30 in people with type 2 diabetes. J Med Econ 2015;18(4):263–272. PMID:25426701. doi:10.3111/13696998.2014.991791
  5. Gupta V, et al. Predictive and explanatory factors of change in health-related quality of life after starting insulin analogs. ADA abstract, June 2015.
  6. Shafie AA, Gupta V, Baabbad R, Hammerby E, Home P. An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naïve people with poorly controlled type 2 diabetes. Diabetes Res Clin Pract 2014;106(2):319–327. PMID:25305133. doi:10.1016/j.diabres.2014.08.024
  7. Gupta V. Glucagon-like peptide-1 analogues: an overview. Indian J Endocrinol Metab 2013;17(3):413–421. PMID:23869296. PMCID:PMC3712370. doi:10.4103/2230-8210.111625
  8. Talwalkar PG, Gupta V, Kovil R. Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: results from the Mumbai cohort of the A1chieve study. Indian J Endocrinol Metab 2013;17(Suppl 2):S516–S520. PMID:24404494. PMCID:PMC3872902. doi:10.4103/2230-8210.122107
  9. Kalra S, Gupta V. The diversity of diabetes. In: Bajaj S, ed. ESI Manual of Clinical Endocrinology. Hyderabad: Endocrine Society of India; 2012. p.3–5.
  10. Gupta V. Pleiotropic effects of incretins. Indian J Endocrinol Metab 2012;16(Suppl 1):S47–S56. PMID:22701844. PMCID:PMC3354942. doi:10.4103/2230-8210.94259
  11. Gupta V, Kalra S. Choosing a gliptin. Indian J Endocrinol Metab 2011;15(4):298–308. PMID:22029001. PMCID:PMC3193779. doi:10.4103/2230-8210.85583

Bones: Osteoporosis & Parathyroid Disease

  1. Gupta V. Normocalcemic primary hyperparathyroidism in a patient with severe osteoporosis receiving teriparatide. Indian J Endocrinol Metab 2013;17(2):336–338. PMID:23776916. PMCID:PMC3683218. doi:10.4103/2230-8210.109664
  2. Cheng ML, Gupta V. Premenopausal osteoporosis. Indian J Endocrinol Metab 2013;17(2):240–244. PMID:23776895. PMCID:PMC3683197. doi:10.4103/2230-8210.109681
  3. Gupta V. Simultaneous presentation of giant pheochromocytoma, primary hyperparathyroidism, and mixed-medullary-papillary thyroid cancer in MEN 2A. Indian J Endocrinol Metab 2013;17(4):751–755. PMID:23961501. PMCID:PMC3743385. doi:10.4103/2230-8210.113776
  4. Gupta V. Vitamin D: extra-skeletal effects. J Med Nutr Nutraceuticals 2012;1(1):17. doi:10.4103/2278-019X.94632
  5. Gupta V, Shah MA, Shah SK, Shah JM. Osteoanabolics. Indian J Endocrinol Metab 2012;16(3):349–357. PMID:22629498. PMCID:PMC3354839. doi:10.4103/2230-8210.95662
  6. Cheng ML, Gupta V. Teriparatide — indications beyond osteoporosis. Indian J Endocrinol Metab 2012;16(3):343–348. PMID:22629497. PMCID:PMC3354838. doi:10.4103/2230-8210.95661
  7. Gupta V, Patil S, Shah D. Primary hyperparathyroidism associated with vitamin D toxicity in a patient with severe osteoporosis receiving teriparatide. Indian J Endocrinol Metab 2012;16(5):863–864. PMID:23087890. PMCID:PMC3475930. doi:10.4103/2230-8210.100697
  8. Gupta V, Sunavala AJ, Bhansali S, Kakkar R. Parathyroid storm secondary to parathyroid adenoma presenting as acute necrotizing pancreatitis. The Endocrinologist 2009;19(1):6–8. doi:10.1097/TEN.0b013e3181939504

Thyroid & Metabolic Research

  1. Vishal Gupta. Comparison of Efficacy of Liothyronine (T3) 50mcg + Levothyroxine (T4) combination therapy Versus T4 Therapy alone on Cardiac markers In Patients With Hypothyroidism followed for 6 months. ENDO 2026, June 13–16, 2026, Chicago, IL.
  2. Vishal Gupta, Vaishali Teli. EP1532 – ECE_1005 – Comparison of efficacy of Liothyronine (T3) 50 mcg + Levothyroxine (T4) combination therapy Vs T3 25 mcg + T4 therapy vs T4 therapy alone on body weight in patients with hypothyroidism followed for 6 months. European Journal of Endocrinology 2026;195(Suppl 1):lvag096.1688. doi:10.1093/ejendo/lvag096.1688
  3. Gupta V, et al. Effect of oral semaglutide on weight & cardiac biomarkers in patients with hypothyroidism treated using liothyronine + levothyroxine combination therapy. Endocrine Abstracts 2023;94:P349. doi:10.1530/endoabs.94.P349
  4. Gupta V, et al. Role of liothyronine/levothyroxine combination therapy in 70 overweight to obese patients with TSH 2.5–5.0 unable to lose weight. Endocrine Abstracts 2023;90:P235. doi:10.1530/endoabs.90.P235
  5. Gupta V, et al. Compare the effects of levothyroxine therapy versus liothyronine/levothyroxine combination on cardiac biomarkers in 364 patients with hypothyroidism. Endocrine Abstracts 2022;81:P241. doi:10.1530/endoabs.81.P241
  6. Gupta V. Block and replace therapy using propylthiouracil and levothyroxine for Graves’ disease during pregnancy. Indian J Endocrinol Metab 2012;16(4):660–662. PMID:22837941. PMCID:PMC3401781. doi:10.4103/2230-8210.98039
  7. Gupta V, Lee M. Central hypothyroidism. Indian J Endocrinol Metab 2011;15(Suppl 2):S99–S106. PMID:21966662. PMCID:PMC3169862. doi:10.4103/2230-8210.83337

Hepatic & Metabolic Research

  1. Gupta V. Severe liver fibrosis (F4) assessed via liver Fibroscan is associated with elevated NT-proBNP in asymptomatic type 2 diabetes mellitus patients receiving SGLT2i therapy. Diabetes 2024;73(Suppl_1):470–P. doi:10.2337/db24-470-P
  2. Gupta V. Serum triglyceride better indicator compared with FIB-4 score for diagnosis of liver fibrosis assessed via liver Fibroscan in Indian patients with type 2 diabetes mellitus receiving SGLT2i therapy. Diabetes 2024;73(Suppl_1):1589–P. doi:10.2337/db24-1589-P